Buy Rating Reaffirmed for Prime Medicine on Strong Cash Position and Promising Technology Platforms
Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
FDA Approves groundbreaking drug for schizophrenia treatment
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
Strategic Focus and BMY Collaboration Bolster Prime Medicine’s Financial Outlook: Hold Rating Affirmed
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...
ScienceAlert54m
First New Schizophrenia Treatment in Decades a Much-Needed Alternative
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...